moneyheap
PEPG · Analysis updated Nov 11, 2026, 9:46 AM ET
Why is PepGen (PEPG) stock moving?
PepGen more than doubled on Nov 10, closing at $4.61 after trading as high as $6.45. Volume was about 106M shares, against a typical volume of about 1M. The trigger was Phase 2 FREEDOM2-DM1 data for PGN-EDODM1 in myotonic dystrophy type 1. The 10 mg/kg dose showed 46.5% mean splicing correction versus 6.8% for placebo. That is nearly double the 25% Dyne reported earlier. No serious or severe adverse events were reported. Cash of $104.8M is guided to fund operations into 2028. Q3 net loss widened to $19.39M. An FDA partial clinical hold on the FREEDOM2 study remains and limits U.S. enrollment. Higher-dose 12.5 mg/kg data is due in H1 2027. The stock has extended its gain in today's session to about $5.53, which is about 20% above Tuesday's close. This suggests buyers are still active. The 52-week range is $1.31 to $7.80, and the shares were still down about 62% year to date before the jump. Analysts' average target of $12.60 is well above the current price. Risks include profit-taking after a move this large, a possible equity raise, the clinical hold, and reliance on one dataset from a small cohort.
News behind the analysis
- PepGen (PEPG) Stock Surges on Positive Mid-Stage Trial Results for Myotonic Dystrophy TreatmentShares nearly doubled in premarket on Nov 10 after Phase 2 FREEDOM2-DM1 data in myotonic dystrophy type 1.
- PepGen Stock Surges 111% on Positive Phase 2 Trial Results for Myotonic Dystrophy TreatmentThe 10 mg/kg dose showed 46.5% mean splicing correction versus 6.8% for placebo, with no severe adverse events. Results from the 12.5 mg/kg cohort are due in H1 2027.
- PepGen updates trial data for muscle disorder therapy (PEPG)Shares climbed nearly 100% premarket after new mid-stage data for lead asset PGN-EDODM1.
- Biotech Stocks In Focus: PEPG Jumps 114%, ZURA Rises 15%, NTHI Gains 13%Healthcare stocks rallied as PepGen surged on positive Phase 2 DM1 data, with improvements in muscle strength and mobility.
- Why Is Penny Stock PepGen (PEPG) Up 114% Today?Analysts rate the stock Strong Buy with an average $12.60 price target. Shares are still down 62% year to date despite the jump.
- PepGen Stock Soars 129% Despite Wider Q3 LossQ3 net loss was $19.39M, or $0.28 per share, versus $18.03M a year earlier. Volume was far above average.
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionPepGen rose 126.6% to $5.42 with a market cap of about $165.5M.
- PepGen (PEPG) Surges 90% on DM1 Trial DataThe result is close to double Dyne's 25% splicing correction. A partial FDA clinical hold still bars U.S. enrollment.
- PepGen (PEPG) Stock Soars 146% After Positive Drug Trial ResultsFive of six participants had more than 20% splicing correction. Cash of $104.8M should fund operations into 2028, and the FDA partial hold remains.